AMGN · News · 20261108N

Repatha Cardiovascular Outcomes Data

AMGEN INC · 2026-11-08 · Importance 17 · Surprise 24

Amgen’s Repatha was cited as benefiting from positive real-world data showing a 20% reduction in heart attack risk. The report says the data reinforced Amgen’s strategy of building its cardiometabolic franchise around existing products. It provides no further detail on the study population or the data’s effect on Repatha demand.

Key facts